Stock events for DarioHealth Corp. (DRIO)
In September 2025, DarioHealth announced a strategic review and completed a private placement, raising $17.5 million, and launched five new contracts with self-insured employers. In November 2025, Q3 earnings were reported with an EPS of -$2.96 and revenue of $5 million, leading to a stock price decline. By December 2025, the company exceeded its 2025 target for new client acquisitions. In January 2026, DarioHealth surpassed 100 peer-reviewed studies and initiated a national rollout with UnitedHealthcare. As of March 2026, Q4 2025 earnings were expected, and the stock price had been volatile and underperformed the healthcare services industry and broader market. On March 6, 2026, the stock price fell by 2.90% and was down by 16.02% over the preceding 10 days.
Demand Seasonality affecting DarioHealth Corp.’s stock price
Specific details regarding the seasonal demand for DarioHealth's products and services were not explicitly provided in the available information.
Overview of DarioHealth Corp.’s business
DarioHealth Corp. is a digital health company focused on chronic condition management through a multi-condition digital therapeutics platform. It offers personalized interventions for diseases like diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, utilizing data analytics and coaching. Key products include Dario Connect, Dario Mind, Dario Move, and a self-care application and virtual coaching platform. The company operates on a B2B2C model, focusing on recurring revenue from self-insured employers and health plans.
DRIO’s Geographic footprint
DarioHealth Corp. operates globally in the United States, Canada, the European Union, Australia, and New Zealand, with offices in New York, USA, and Israel.
DRIO Corporate Image Assessment
DarioHealth has maintained a positive brand reputation, being recognized as a leader in digital health for its innovative solutions. The Dario app has high user ratings, and its Blood Glucose Monitoring System was recognized as the "Best Glucometer for Data Management." The company was included in "The Global Digital Health 100" list and surpassed 100 peer-reviewed scientific studies, reinforcing its evidence-based approach.
Ownership
DarioHealth Corp.'s ownership is distributed among institutional investors, internal stakeholders, and the public market. Major institutional owners include Nantahala Capital Management, LLC, Vanguard Group Inc, Geode Capital Management, Llc, and BlackRock, Inc. Institutional investors hold approximately 8.34% to 12.70% of the company's stock, while insiders hold around 9.57%. The general public accounts for approximately 80.59% of the stock. Adam Stern owns the most shares.
